• Mashup Score: 0

    23andMe reports results of the Phase 1 clinical trial for a potential new cancer therapy, an antibody referred to as 23ME-00610, 23ME’610

    Tweet Tweets with this article
    • An Update on #23andMe’s #ClinicalTrial for 23ME-00610 in Patients https://t.co/2nKiUlTdXA #23ME00610 #CD200R1 #Immunotherapy #Tcells "To all our customers who participate in our research – over 80% of you – you help make advancements like this possible. Thank you. We know that… https://t.co/QIogPgohov https://t.co/O65wEk18xW